Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
Orca prepares to make market plunge after phase 3 win
Orca-T offers “good efficacy and low toxicity,” CEO Ivan Dimov said, noting that the combination of features represents the "holy grail" in the space.
Gabrielle Masson
Mar 17, 2025 7:00am
Amgen’s late-stage obesity trials expected to read out in ‘27
Mar 5, 2025 1:58pm
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
Galectin's stock halves after phase 3 MASH trial misses goal
Dec 20, 2024 2:40pm
Merck's HIV combo treatment meets efficacy bar in phase 3 trials
Dec 19, 2024 11:54am
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am